fbpx

SIGN IN YOUR ACCOUNT TO HAVE ACCESS TO DIFFERENT FEATURES

FORGOT YOUR PASSWORD?

FORGOT YOUR DETAILS?

AAH, WAIT, I REMEMBER NOW!
+1 786 238 2170

Global Stem Cells GroupGlobal Stem Cells Group

  • Home
  • Our Story
  • Advisory Board
  • Investors
  • Companies
  • Press Releases
  • Blog
CONTACT
  • Home
  • Posts tagged "regenerative medicine"
February 6, 2023

Tag: regenerative medicine

ISSCA’s On-site Training in Portugal

Wednesday, 25 January 2023 by Stem Cells Group
ISSCA on-site training Portugal

MIAMI, Florida, January 23, 2023 – The Global Stem Cells Group (GSCG) announces its long-awaited hands-on training this March 9th, 10th & 11th, 2023

The GSCG, through its International Society for Stem Cell Application (ISSCA) division, is holding a personalized, hands-on training course at Regenera clinic, located in Oeiras, Lisboa, Portugal. Industry-leading instructors across the regenerative medicine field will lead this onsite training course. We believe this course is a Total Solution for clinics as ISSCA teams will teach and train doctors and caregivers on the recent advances in regenerative medicine and cellular-based treatments.

Lisboa’s First On-site Training

Benito Novas, CEO of Global Stem Cells Group and Vice President of ISSCA, notes that “regenerative medicine is the future of health and beauty industries as more research is conducted and products developed for doctors to offer a superior service.”

Benito adds, “the training course will take a highly visual format with global experts interacting with trainees and live patients used to teach about different stem cell reintegration and procedural techniques with locally available tools and facilities.

The Lisboa training is the first in the country to bring clinics into the fold of regenerative medicine and stem cell treatments. Regenera clinic will be the first to be ISSCA certified and apply cellular therapies and regenerative medicine. Dr. Roni Lara Moya will be appointed Portugal Chapter director on 9th March.

The course design considers the needs of local trainees using a thorough scheduling process. Initial consultations between the trainees and ISSCA will inform equipment and kits availability, materials, underlying costs, and any other needs to be met during the main event.

What is the On-site Training About?

The following are some of the areas the onsite-training course will focus on:

1. Learning from Experts

A panel of stem cell therapy and regenerative medicine experts will lead the one-on-one training sessions. Cell therapy, skin regeneration techniques, bone marrow extraction, tissue engineering, and many more applications of advanced technologies to advance personalized health will be practically illustrated.

2. Trainees-Centered Treatment Protocols

The training course is personalized to every doctor and clinician’s specialization and the illness they are targeting. For example, stem cell treatment sessions will include various reintegration methods based on patients’ medical history and condition. The trainees will also have a first-hand view of how technology pushes the boundaries of regenerative medicine from research to the derivation of cell lines and, as we are all working to the possible future of genetic alteration.

Local nurses and medical assistants will also have a chance to be part of the process by going through a fully skilled procedural session that improves their assistance to the doctors.

3. International Certification

As an acclaimed stakeholder in regenerative medicine and stem cell treatment, ISSCA offers globally recognized certification to doctors and practitioners, highlighting their fascinating journey in this highly demanded field. According to the appointed chapter director of Portugal, Dr. Roni Lara Moya- “the upcoming onsite training is one of its kind ever conducted in the country. Dr. Moya asserts that “the collaboration between ISSCA and Regenerative Biomedicine Regenerative Clinic stems from a growing demand for new technologies and cutting-edge treatments that support patients’ positive health outcomes.”

4. Trends in Regenerative & Stem Cell Treatment

The training will cover stem cell and regenerative medicine’s practical, legal, technical, and ethical aspects. Laws, technological developments, and ethical concerns will be a critical part of the training course.

All are welcome to share the fantastic excitement of stem cell science and its promising future.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.

The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.

ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.

About Global Stem Cells Group:

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.

GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Bone Marrow ExtractionCellular-based TreatmentsISSCAregenerative medicineSkin Regeneration Techniquestissue engineering
Read more
  • Published in Press Releases
No Comments

Mesenchymal Stem Cells For Cardiovascular Diseases

Tuesday, 10 January 2023 by Stem Cells Group

Despite progress in cardiovascular research, cardiac pathology continues to be one of the most common causes of morbidity and mortality in the world. Stem cell-based therapy has been recognized as an innovative strategy for the repair, regeneration and functional recovery of the myocardium, hence, once the animal research stage has been overcome, most clinical trials aimed at evaluating the safety and effectiveness of regenerative medicine in cardiovascular diseases have focused on angina pectoris, myocardial infarction and chronic cardiomyopathy. Although the current evidence of benefit is not conclusive, the evidence in favor of favorable results is growing.

In some cases, stem cell therapy can provide an effective treatment or alternative for diseases or disorders for which there is no effective treatment. Because these cells are capable of dividing into a wide range of lineages and tissues, they can be used to treat various diseases by repairing, replacing, and regenerating tissues.

It is unclear how umbilical cord mesenchymal stem cells act on the heart, but previous studies have shown that they possess an anti-apoptotic effect. The induced cardiomyocytes can form discs interspersed with myocytes from the host cells, creating a functional syncytium that will help contract the heart. Mesenchymal stem cells can improve cardiac function and reduce damage caused by cardiovascular disease, since they stimulate endogenous repair mechanisms, the regulation of the immune response, tissue perfusion and the proliferation of the resident heart rate, thereby improving cardiac function and reducing damage severity.

Refractory angina

This syndrome, characterized by persistent angina despite standard medical treatment, is often not revascularized due to diffuse coronary lesions or severe comorbidities.

In 2017, a review included 13 clinical studies, with 1061 patients and 12 months of follow-up on average, indicating cell therapy has emerged as a tool for managing these patients. Although the available data are inconclusive, the authors conclude that stem cell-based therapy could be a viable addition to conventional treatment options for refractory angina, given the paucity of therapeutic alternatives.

There was a reduction in mortality at two years after a meta-analysis in 2018, involving 304 patients, showed improved exercise tolerance and reduced angina attack frequency at three, six and 12 months. An additional meta-analysis published in March 2019, involving 526 patients monitored for 14 months, showed that patients treated with stem cells had fewer serious adverse effects, fewer deaths, fewer angina attacks, and fewer antianginal medications than those treated with conventional management.

A third meta-analysis from 2019, with 269 patients and 15 months of follow-up on average, reports the following results: decreased all-cause mortality, decreased frequency of angina and increased exercise time, with no increase in adverse reactions.

Cardiomyopathy (ischemic and non-ischemic)

Despite optimal medical and surgical management, many patients with heart failure undergo long-term myocardial remodeling that does not allow them to restore their ventricular function. This is because current treatment protocols cannot reverse the loss of cardiomyocytes due to cardiomyopathy. Since inflammatory responses continue over time as a central mechanism in the development of heart failure, it was of interest to investigate the anti-inflammatory, antifibrotic, and immunomodulatory properties of stem cells in patients with ischemic and non-ischemic cardiomyopathy.

In a review of five clinical studies published between 2017 and 2018, including 605 patients, the authors conclude that cell therapy is safe, causes immunomodulatory effects, improves functional capacity, and adds clinical benefits to standard therapies. According to them, the results are promising, and further evidence strengthening is recommended.

Based on a meta-analysis published in May 2019, involving 20 investigations and 1418 patients evaluated for an average of 21 months, stem cells improved cardiac function indicators (LVEF and LVESV), walking distance, functional classification of heart failure, quality of life, and mortality as compared to controls. Hospitalizations and serious adverse events were not different from those in the control group.

In a recent review of 9 studies involving 612 patients with heart failure, improvement was found in clinical and paraclinical parameters, evaluated on average for 9 months. According to the authors, stem cells are an effective therapy for the treatment of heart failure, improving patient prognosis and ability to exercise.

Acute myocardial infarction (AMI)

The application of stem cells was associated with a significant increase in left ventricular ejection fraction (LVEF) and other variables indicative of improved ventricular function and modification of remodeling in patients with AMI receiving timely percutaneous coronary intervention (PCI) and conventional medication in different studies. Even coronary artery bypass grafting with stem cells offers greater benefits. A number of studies have also shown that intravenous administration could be a more efficient and effective method of treating the heart or coronary arteries than direct application, with logistic, safety, and cost advantages.

Stem cell therapy is evidenced to be a safe way to treat cardiovascular diseases, as it shows an anti-apoptotic effect, reduction of lesion size, improvement of cardiac function through regulation of the immune response, adequate tissue perfusion and activation of growth factors.
We still need to explore a lot of ground, in terms of these and other conditions. You can learn more about regenerative medicine and stem cells by enrolling in our international certification program at www.issca.us

global stem cells groupISSCAregenerative medicineregenerative medicine trainingstem cellsStem Cells Coursestem cells therapystem cells training
Read more
  • Published in Corporate News / Blog
No Comments

Atherosclerosis obliterans grade IV: Application of Autologous Stem Cells

Tuesday, 03 January 2023 by Stem Cells Group

Atherosclerosis is the most common form of arterial occlusive disease in adults.  About 15 percent of adults over 55 years of age suffer from critical ischemia, the most severe form of this disease.

Due to the gradual aging of the population and the growing number of people in their third age group, a number of studies have been conducted in order to improve the prognosis of atherosclerosis obliterans and to find alternatives to the mutilation of the extremities. As a general rule, chronic ischemia of the lower limbs should be treated to alleviate symptoms, particularly pain, prevent disease progression, and reduce the rate of amputations. In most patients with critical ischemia, the main goal is to preserve the affected limb.

The development of regenerative medicine is closely linked to the development of new knowledge about embryonic and adult stem cells, as well as the regenerative and therapeutic potential of stem cell therapy. The use of adult stem cells in the treatment of peripheral artery diseases has been demonstrated as a therapeutic agent for inducing angiogenesis. Recent preclinical studies as well as the pioneering clinical studies indicate that bone marrow-derived mononuclear cells (MBMCs) can enhance tissue vascularization in ischemic limbs, with results similar to those obtained with peripheral blood stem cells supply.

Cuba presented the first studies carried out in 2004 at the Institute of Hematology of the “Enrique Cabrera” hospital in Havana City, which achieved encouraging clinical results and had very few adverse effects in recent years.

A progressive rise in the accumulated experience with stem cells was also observed in Pinar del Rio in 2005, as the first 10 cases were carried out. The rising ease of obtaining this type of cell has made research and applications with these cells advance rapidly with great expectations in terms of clinical application.

A study published by Dia-Diaz, et al. in the Journal of Medical Sciences of Pinar del Rio examined 296 patients with grade IV atherosclerosis obliterans between 2009 and 2019. During the study, autologous stem cells were injected intramuscularly from peripheral blood. Within four weeks, pain relief was observed, as well as an increase in the pain-free claudication distance. Angiography after treatment revealed collateral vessel formation. The limb was saved in 201 patients (68%), while 95 cases (32%) presented amputation criteria. Complications were not reported following the procedure.

The study demonstrated the effectiveness of the implantation of autologous stem cells obtained from peripheral blood, as well as the favorable evolution of patients, clinical improvement of rest pain, walking distance without claudication and ankle-brachial pressure index.

We still need to explore a lot of ground, in terms of these and other conditions. You can learn more about regenerative medicine and stem cells by enrolling in our international certification program at www.issca.us

global stem cells groupregenerative medicineregenerative medicine trainingstem cellsStem Cells Coursestem cells training
Read more
  • Published in Corporate News / Blog
No Comments

The emerging role of MSC-derived exosomes in Regenerative Medicine

Tuesday, 27 December 2022 by Stem Cells Group

In recent years, MSCs have been introduced as respectable candidates for regenerative medicine due to their pro-angiogenic, anti-apoptotic, and immunomodulatory attributes. A variety of human tissues can be used as a source of mesenchymal stem/stromal cells (MSCs), ranging from bone marrow (BM) to umbilical cord (UC). These cells are typically multipotent and can differentiate into a variety of cell types. MSCs have been studied extensively for potential applications in cardiomyopathy, neurodegenerative disorders, spinal cord injuries (SCI), kidney injuries, liver injuries, lung injuries, and even cancer. According to current research, MSC-derived extracellular vesicles (EVs) contribute to MSC-exerted therapeutic benefits.

As defined by the International Society for Extracellular Vesicles (ISEV), EVs are lipid bilayer particles secreted by cells that do not replicate. EVs can be categorised into three subclasses based on size and biogenesis procedures: surrounding exosomes (50-150 nm), microvesicles (MVs) (100-1000 nm), and apoptotic bodies (ApoBDs) (500-5000 nm). In order for exosomes to be produced, multiple steps must occur; endosomes must be created from the plasma membrane, intraluminal vesicles must be formed within multivesicular bodies by inward budding, the MVB must merge with the plasma membrane, and finally the internal vesicles must be released.

By transmitting their molecules, such as proteins, messenger RNA (mRNA), and microRNAs (miRNAs), MSC exosomes stimulate phenotypic changes and subsequently modify regenerative programs of target organs. A number of mechanisms are involved in phenotypic alterations, including prevention of apoptosis, cell proliferation, immunomodulatory reactions, attenuation of oxidative stress, and improving oxygen supply to recipient cells. By supporting mitochondrial transfer, MSC-exosomes can suppress inflammatory cytokine production and induce phenotype 2 alveolar macrophages (M2), leading to acute lung injury (ALI) rescue. It has been demonstrated that the transmission of miRNAs from MSC-exosomes to recipient cells is responsible for the restoration of damaged kidneys, hearts, livers, and brains

Various cells continuously form and secrete exosomes, including lymphocytes, platelets, mast cells, intestinal epithelium, dendritic cells, neoplastic cell lines, microglia, neurons, and MSCs. Studies have shown that exosomes play an important role in cell-to-cell communication as well as several physiological and pathological processes. Despite their inherent biological activities, exosomes have recently been introduced as encouraging drug carriers because of their small size, high biocompatibility, and ability to hold different therapeutic ingredients, including proteins, nucleic acids, and small molecules. There have been reports showing the usefulness of MSCs-exosomes for treating a variety of ailments, such as lung, kidney, liver, neurodegenerative, cardiac, and musculoskeletal diseases, as well as skin wounds in vivo.

As well as their remarkable therapeutic effects, MSC-EVs derived from diverse sources also possess a variety of physiological functions that may affect their therapeutic application. In a wide range of human disorders, MSC-exosomes are considered an effective alternative to whole-cell therapy because of their low immunogenicity and improved safety profile. Although MSC-exosome applications still face various challenges, their benefits and capabilities are attracting increasing interest.

To learn more about exosomes and their clinical applications or if you’re interested in boosting your clinical practice with exosomes, go to our website www.cellgenic.com

global stem cells groupregenerative medicineregenerative medicine trainingstem cellsStem Cells Coursestem cells training
Read more
  • Published in Corporate News / Blog
No Comments

Global Stem Cells Group announces the opening of a new Stem Cell Center in Bandung, Indonesia

Thursday, 15 December 2022 by Stem Cells Group

Miami, FL, December 12, 2022 – Global Stem Cells Group (GSCG) is pleased to announce the opening of a new Stem Cell Center in Bandung, Indonesia in partnership with the Dr. Yanti Aesthetic Clinic. This joint venture will be the second in the country as they already have another facility in the stunning City of Surabaya.

The New Global Stem Cell Group Facility is Expected to Transform the Regenerative Medicine Field

The GSCG’s new center in Bandung aims to increase awareness about the benefits of regenerative medicine. Its launch strengthened the relationship between GSCG and the Dr. Yanti Aesthetic Clinic. This new facility is expected to transform regenerative medicine in the following ways:

  • Offering accessible stem cell therapy to Indonesians;
  • Promoting regenerative medicine technology; and
  • Inspiring other doctors and industry experts to explore regenerative medicine.

Top Government Officials Attended the Launch of the Global Stem Cell Group Office in Bandung

The launch of the new Global Stem Cell Group facility in Bandung was a remarkable event in the medical field. The Minister of Tourism was among the top officials that witnessed the launch. Furthermore, the office of the Vice President sent several representatives.

What the President of Global Stem Cell Group Has to Say

Benito Novas, the president of the GSCG, was among the top industry specialists that graced the launch of the company’s second facility in Indonesia. According to him, GSCG wants to make regenerative medicine readily available for patients worldwide. Likewise, the company is encouraging more doctors to adopt stem cell therapy’s clinical and aesthetic applications in their work.

Benito Novas said: “We are dedicated to making it possible for both doctors and patients in all parts of the world to experience the benefits of regenerative medicines. The company is expanding and establishing itself as a market leader.”

The Director of the Dr. Yanti Aesthetic Clinic Appreciates GSCG

Dr. Yanti Kushmiran, director of the DR. Yanti Aesthetic Clinic, is once again honored to be part of this step into the future of regenerative medicine with its second Stem Cell Center in Indonesia together with the leading company Global Stem Cells Group.

Regarding this new clinic, Dr. Yanti says “We are honored to be part of GSCG, which has a more than 10-year track record in the market and a strong international reputation and to open a second cell therapy and regenerative medicine center facility under the Stem Cell Center brand. We will be able to provide more services to our patients as a result of this new partnership.”

Another GSCG Clinic is Opening in Indonesia by January 2023

The Global Stem Cell Group will continue increasing patients’ access to advanced regenerative medicine. As a result, the company plans to open another branch in Jakarta, the Capital of Indonesia. GSCG and its partners plan to launch this third facility in January 2023.

About Global Stem Cell Group

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.

GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

BandungDr. Yanti Aesthetic Clinicglobal stem cells groupGSCGIndonesiaregenerative medicineStem Cell Centerstem cell medicinestem cell therapy
Read more
  • Published in Press Releases
No Comments

New advances in osteoarthritis therapy with stem cells

Friday, 18 November 2022 by Stem Cells Group

Osteoarthritis is a rheumatic pathology that damages the articular cartilage.  By joining two bones through the joint capsule, the joints are able to move, providing us with functional autonomy. An inner fluid called synovial fluid is usually found within joints, which is produced by the synovial membrane.  Articular cartilage covers the ends of the bones that form the joint.  As a result of damage to this articular cartilage, pain, stiffness, and functional impairment occur. Osteoarthritis is the most common joint disorder, usually beginning between the ages of 40 and 50, affecting to some degree almost everyone over the age of 80. Typically, osteoarthritis affects the spine, shoulders, fingers, hips, knees, and toe joints.

Stem cell therapies have the potential to treat a broad spectrum of diseases. Whether it’s rhizarthrosis, diabetes, neurodegenerative diseases, spinal cord injuries, or heart disease. By utilizing stem cells, regenerative medicine is capable of repairing tissues in affected areas.  The main difference between lipo gem therapy and other treatments for osteoarthritis is that lipogem therapy regenerates cartilage, avoids surgery and its sequelae, and improves the quality of life for patients.

The potential for medical treatments with stem cells and their by-products is currently very high.  In the field of sports medicine and traumatology, one of the most outstanding advances has been made for the first time in decades recently: Spanish scientists have achieved a degree of tendon regeneration in 100% of injured patients, resulting in a decrease in pain and a return to sport within two months, and just six months after the trial was completed.

A research performed by the Institute of Regenerative Tissue Therapy (ITRT), published by the prestigious American Journal of Sports Medicine. Demonstrates how this therapy regenerates chronic lesions in the patellar tendon and opens up a new therapeutic option for this tissue, which was considered impossible to regenerate.

In most patients, fat tissue can be harvested minimally invasively (under local or general anesthesia), providing a highly viable MSC population regardless of donor age. Similar to MSCs derived from other tissues, adipose tissue-derived MSCs have regenerative potential. As osteoarthritis is a very common joint disease, and knee osteoarthritis is the most common form, it is necessary to review scientific literature on osteoarthritis treatments with stem cells, like lipogems.

Lipogems Therapy

Lipogems therapy is a novel procedure that enhances the body’s natural ability to heal itself through the innovative power of science and biotechnology. The Lipogems method involves injecting mesenchymal stem cells into the joints.  Adipose-derived mesenchymal stem cells have enormous regenerative potential. They also have a regenerative capacity independent of their age. Even older individuals can benefit from this procedure.

Injection of mesenchymal stem cells into the knee, particularly in the early stages of osteoarthritis, can stop the process of inflammation and degeneration, especially in the less advanced stages of the disease. In addition to preventing progressive physical deterioration of the articular cartilage, this treatment contributes significantly to a patient’s well-being and prevents the installation of knee prostheses.

Patellar tendinopathy, physiotherapeutic treatment and stem cell therapy

Injuries to the patellar tendon that connects the kneecap to the tibia are known as patellar tendinopathy or patellar tendinitis. The patellar tendon works with the muscles in the front of the thigh to extend the knee so you can kick, run and jump. Athletes who perform frequent jumping in their sports, such as basketball and volleyball, are most likely to suffer from patellar tendonitis. However, people who don’t engage in jumping sports may develop patellar tendonitis. Patients with patellar tendinitis usually begin treatment with physical therapy to stretch and strengthen their knee muscles.

Strength training with eccentric resistance is one of the most common treatments for tendinopathies. Alternatively, it has been demonstrated that bone marrow-derived mesenchymal stem cells (MSCs) can regenerate injured patellar tendons. Within six months of treatment, it has been observed that the structure of this tissue – which is always difficult to treat – is restored, reaching a regeneration of 40% in all injured persons, with a gradual improvement that eventually becomes complete.

It has been found that traditional management methods, including isometric or eccentric exercises, shock wave therapy, and even surgery, are not effective. As part of a rehabilitation program in chronic patellar tendinopathy, autologous expanded bone marrow mesenchymal stem cells (BM-MSC) or leukocyte-poor platelet-rich plasma (Lp-PRP) may be effective in reducing pain and improving activity levels. Traditional management, which includes isometric or eccentric exercises, shock wave therapy, and even surgery, has limited success. A combination of autologous expanded bone marrow mesenchymal stem cells (BM-MSCs) and leukocyte-poor platelet-rich plasma (Lp-PRP) and rehabilitation may reduce pain and improve activity levels in active participants with chronic patellar tendinopathy. 

To learn more about stem cells, cellular therapies and keep up to date with all the information about regenerative medicine and its advances, sign up for our international certification in regenerative medicine at www.issca.us

global stem cells groupregenerative medicinestem cellsStem Cells Coursestem cells therapystem cells training
Read more
  • Published in Corporate News / Blog
No Comments

Regenerative Medicine – An Overview On Stem Cell Therapy

Thursday, 10 November 2022 by Stem Cells Group

Stem cell therapy is a form of regenerative medicine designed to repair damaged cells within the body by reducing inflammation and modulating the immune system. This phenomenon makes stem cell therapy a viable treatment option for a variety of medical conditions.

What is stem cell therapy?

The term stem cell therapy refers to any treatment involving the use of viable human stem cells including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) and adult stem cells. By being able to differentiate into the specific cell types necessary for repairing diseased tissues, stem cells are the ideal solution for tissue and organ transplantation.

As stem cell-based therapies are complex, researchers often seek stable, safe, and readily available sources of stem cells that can differentiate into multiple lineages. As such, choosing stem cells with clinical applications in mind is of the utmost importance

The hierarchy of stem cells

In general, stem cells fall into three categories. In addition to self-renewal, all three share a unique ability to differentiate. However, stem cells do not exist in a homogeneous form, but rather in a developmental hierarchy. Among all stem cells, totipotent cells are the most basic and least developed. These cells are capable of developing into a complete embryo while forming the extraembryonic tissue at the same time. During the fertilization of the ovum, this unique property begins and ends when the embryo reaches the stage of four to eight cells.

As the cell divides further, it loses its totipotency property and becomes a pluripotent cell, capable of dividing into each of the three embryonic germ layers (ectoderm, mesoderm, and endoderm). These cells are referred to as “embryonic stem cells” and are isolated from the inner cell mass of the blastocyst after the embryo is destroyed.

The property of pluripotency is lost with successive divisions, resulting in a more limited differentiation capability in which the cells can only differentiate into limited types of cells related to their origins. “Adult stem cells” have this property, which helps maintain homeostasis throughout the organism’s lifespan. It is known that adult stem cells are present in most specialized tissue types of the body in a metabolically quiescent state, including bone marrow and oral and dental tissue.

According to many authors, adult stem cells are the gold standard for stem cell-based therapies. A number of trials involving adult stem cells have shown promising results, especially in the transplantation of hematopoietic stem cells.

Stem cell research for treating disease

In 2006, Shinya Yamanka achieved a scientific breakthrough in stem cell research by generating cells with the same properties as embryonic stem cells. In fully differentiated somatic cells, namely fibroblasts, four transcription factors were transiently over-expressed, including OCT4, SOX2, KLF4, and MYC. As a result of the discovery of these cells, stem cell research has been transformed ever since. Similar to embryonic stem cells, these cells are capable of dividing into any of the germ layers. As a result of the development of iPSC technology, disease identification and treatment have become more innovative. IPSCs are therefore promising as a source of pluripotent derived patient-matched cells that can be used for autologous transplants because they can be generated from the patient’s own cells. 

It is believed that stem cells, due to their unique capacity to regenerate, may hold new potential for treating diseases such as diabetes and heart disease. Despite this, there remains much work to be done in the laboratory and clinic to determine how these cells can be used in regenerative or reparative medicine to treat diseases.

Studies of stem cells in the laboratory allow scientists to gain a better understanding of the cells’ essential properties as well as what makes them different from specialized cell types. Researchers are already using stem cells to test new drugs and develop model systems for studying normal development and identifying the causes of birth defects in the laboratory.

The study of stem cells continues to advance our understanding of the development of an organism from a single cell and of how healthy cells replace damaged cells in adult organisms. Research on stem cells is one of the most fascinating areas of contemporary biology, but, as with many fields of science that expand rapidly, it raises as many questions as it answers.

To learn more about stem cells, cellular therapies and new medical protocols using exosomes sign up for our international certification in regenerative medicine at www.issca.us 

ISSCAregenerative medicineregenerative medicine trainingstem cellsStem Cells Coursestem cells therapystem cells training
Read more
  • Published in Corporate News / Blog
No Comments

Global Stem Cells Group, Announces Launch of New Stem Cells and Regenerative Medicine Clinic in CDMX

Monday, 31 October 2022 by Stem Cells Group

Miami, FL, October 28, 2022 – Global Stem Cells Group announces a new partnership that enhances its goal of establishing its therapies and technology to meet market demand in populated areas of the world.

This collaboration with STEM LIFE clinic’s new facility and Dr. Vanessa Rodriguez Pares, currently one of the most prestigious aesthetic clinics in Mexico City, is expected to promote a high level of service in regenerative medicine throughout the country.

As part of this effort, the International Society for the Application of Stem Cells (ISSCA) has granted Dr. Vanessa Rodriguez Peers affiliation and use of their brand, products, therapies and training on how to apply stem cell therapies.

“This new partnership aims to expand the Global Stem Cells Group (GSCG) brand and create centers of excellence in cell therapy to meet the high demand in the Mexican market,” said Benito Novas, CEO of Global stem cells group “GSCG is rapidly expanding its global operations as it seeks to become a major player in the lucrative regenerative medicine industry. To achieve our expansion plans, our organization is partnering with healthcare providers specializing in regenerative medicine with at least five years of experience in the healthcare sector.”

Stem cell therapy is becoming an increasingly effective clinical solution for treating conditions that traditional or conventional medicine only offers within palliative care and pain management. Patients around the world are seeking a natural regenerative alternative without the potential risks and side effects sometimes associated with conventional pharmaceuticals.

The opening of this center, which will include the construction of an autologous tissue processing laboratory and an allogeneic tissue bank, will help stem cell therapy and regenerative medicine finally move from being an elective procedure to being accessible to patients throughout Mexico.

About Dr. Vanessa Rodriguez Pares

Dr. Vanessa Rodriguez Pares is a specialist in aesthetic medicine and surgery, with special attention to obesity and overweight in all ages. Management of cosmetic surgery with a comprehensive approach to the patient, taking into account their safety and their physical, psychological and emotional needs. Specialist in ULTHERAPY treatment to perform facelift without surgery. In addition to extensive experience with cellular therapies and regenerative medicine since 2016, specializing in anti-aging techniques, hair regeneration, facial aesthetics with stem cell assisted lipotransfer among other techniques.

About the Global Stem Cell Group

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products, and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators, and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website

www.stemcellsgroup.com or call +1 305 560 5331

Anti-aging TechniquesFacial Aestheticsglobal stem cells groupGSCGhair regenerationInternational Society for the Application of Stem CellsISSCALipotransferregenerative medicinestem cell therapySTEM LIFE clinic
Read more
  • Published in Press Releases
No Comments

Global Stem Cells Group Announces the Opening of a Multi-Specialty Regenerative Medicine Center in Cancun

Sunday, 30 October 2022 by Stem Cells Group

Global Stem Cells Group has just announced the official opening of a new multi-specialty regenerative medicine center in Cancun. The new center is intended to incorporate different treatments based on regenerative medicine as well as to serve as a multi-specialty training center in the field of regenerative medicine and cellular therapies, offering doctors and patients the most advanced treatments in cell therapy worldwide.

The Cellular Hope Institute, as this facility was named, will also strive to pursue several objectives that will benefit patients and medical experts worldwide. It is expected to be a medical hub that will offer the best treatments for patients suffering from multiple conditions such as autoimmune deficiencies, sports injuries, chronic degenerative diseases and pediatric diseases.

Benito Novas says. “Our goal is to solve the problem and alleviate the condition, not just attempt to treat it. We are committed to offering top-notch technology available and quality care, emphasizing that our patients are always our number one priority. Our highly qualified team of experts are always ready to assist you at Cellular Hope Institute.”

The Center utilizes comprehensive stem cell treatment protocols that employ well-targeted combinations of Exosomes, allogeneic human Mesenchymal cells, autologous bone marrow and Adipose derived stem cells to treat the diseases and conditions listed above. The treatment plans are mostly focused on a systemic or whole-body approach to ensure patients receive the highest quality and quantity of cellular products available today.

Cellular Hope Institute  will also be a center that will offer specialized regenerative medicine courses for physicians. Primarily, it is expected to be a resource center that will train doctors to incorporate modern regenerative medicine practices into their offices.

Our focus is to incorporate multiple specialties into separate programs within this training hub. Industry experts are expected to join the facility and offer the latest information about various compounds in the stem cell market, such as Mesenchymal stem cells, umbilical cord derived products, exosomes and many other stem cell products. We plan to target physicians who want to incorporate the treatment solutions into their practices, and the separate programs are designed to reach a wide array of practitioners.

In addition, Cellular Hope Institute also expects to have a fully functional manufacturing laboratory that seeks to elaborate the cellular products. The laboratory is already equipped with the latest and innovative technology to ensure it offers the best stem cell products and treatments. The facility will have enough capacity to store and distribute cellular products, including cells and exosomes. We expect it to be the primary supply center for doctors all over Mexico. The inauguration will mark a step closer to pursuing cell therapy, regenerative medicine, and modern tissue engineering options globally.

The opening of this center is an effort by Global stem Cells Group to continue its mission to reduce the suffering of patients and offer a new healing alternative. It is the commitment of scientists and doctors who believe in the potential of regenerative medicine as a standard treatment that should be in every doctor’s office worldwide.

To learn more about the cellular hope institute, visit its website here: https://cellularhopeinstitute.com/

AdiposeAllogeneic Human Mesenchymal CellsAutoimmuneAutologous Bone MarrowCellular Productscellular therapiesChronic Degenerative DiseasesExosomesregenerative medicineRegenerative Medicine CenterSports Medicinestem cells
Read more
  • Published in Press Releases
No Comments

GSCG Announces the Appointment of Dr. Rafael Moguel as New Chief Medical Officer (CMO) of Cellular Hope Institute Cancun

Sunday, 30 October 2022 by Stem Cells Group

Global Stem Cells Group (GSCG) has announced the appointment of Dr Rafael Moguel as the new Chief Medical Officer (CMO) of Cellular Hope Institute Cancun.

Dr. Moguel, Fellow of the Society for Cardiac Angiography and Intervention (SCAI),  Member of the Mexican Society for Interventional Cardiologists, and Member of the Latin American Society for Interventional Cardiology, comes with a wealth of experience and training.

As CMO with vast knowledge and experience, Dr Moguel is expected to change the direction of Cellular Hope Institute Cancun, which offers patients the best treatments in multiple areas, such as sports medicine, pediatric care, chronic degenerative disease, and autoimmunity. It’s a multi-specialty training center for cellular therapies and regenerative medicine, offering the most advanced treatments in cell therapy.

“I have full confidence in the appointment of Dr Rafael Moguel as the CMO of Cellular Hope Institute Cancun,” said Benito Novas, CEO of Global Stem Cells Group. The CEO also expressed his satisfaction in Dr Moguel’s abilities and experience, and is confident that (Dr Moguel) will advance the objectives of Cellular Hope Institute and propel it to new heights.

With his impressive resume, Dr. Moguel has served in various capacities across several top medical institutions. He was the assistant professor for Cardiology and Interventional Cardiology at Hospital 1° de Octubre, where he also handled hemodynamics and internal medicine.

In his acceptance speech, Dr Moguel said, “I want to affirm and reaffirm my commitment to the goals of Cellular Hope Institute.” With his elaborate working experience and professionalism in cellular therapy, he expressed his confidence in rising to the expectations of Cellular Hope Institute.

Dr. Moguel received his medical degree at Universidad Veracruzana in 1983. He holds a valid certification by the Mexican Cardiology Board for Interventional Cardiology. With more than 10,000 interventional procedures, most notably peripheral and brain intervention, coronary, pacemakers and vein interventions, we believe Dr. Moguel has all it takes to propel Cellular Hope Institute to the next level.

The appointment of Dr. Moguel comes barely two months after an earlier announcement by GSCG about opening the multispecialty regenerative medicine center in Cancun. The facility’s main objective is to incorporate different treatments basing on regenerative medicine, and serve as a training center for cellular therapies and regenerative medicine.

We believe Dr. Moguel’s rich background as an assistant professor and head of interventional cardiology and hemodynamics positions him as the best candidate to run Cellular Hope Institute. His experience is expected to make this facility one of the best cellular therapy centers worldwide, and provide more specialized treatment for patients requiring regenerative medicine.

About Cellular Hope Institute

This facility is a center for both patients and medical experts worldwide, and its main objective is to benefit medical experts and patients globally. The facility achieves this objective through offering the best treatments for patients with multiple conditions, such as spinal cord injury, chronic obstructive pulmonary, sports medicine, and autoimmunity, among others. If you need more information about Cellular Hope Institute, please contact us today.

About the Global Stem Cell Group

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products, and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators, and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website.

Autoimmunity Cellular TherapiesChronic Degenerative Diseaseglobal stem cells groupGSCGMSSVPediatric Careregenerative medicineSports Medicinestem cell treatments
Read more
  • Published in Press Releases
No Comments
  • 1
  • 2
  • 3
  • 4

Send Us a Message

  • Home
  • Our Story
  • Advisory Board
  • Investors
  • Companies
  • Testimonials
  • Press Releases
  • Blog

Copyright © 2022 Stem Cells Group | All Rights Reserved

CONTACT US

Datran Center 9100 S Dadeland Boulevard, Suite 1500. Miami Fl. 33156 United States

305-560-5337

info@stemcellsgroup.com

STAY CONNECTED

Get the latest news, updates, and promotions. Follow us on our social networks.

Certification issued by ISSCA and endorsed by the Universidad Autónoma del BENI: UAB and by the Atlantic International University

  • Home
  • Our Story
  • Advisory Board
  • Investors
  • Companies
  • Testimonials
  • Press Releases
  • Blog

Copyright © 2022 Stem Cells Group | All Rights Reserved

CONTACT US

Datran Center 9100 S Dadeland Boulevard, Suite 1500. Miami Fl. 33156 United States

305-560-5337

info@stemcellsgroup.com

STAY CONNECTED

Get the latest news, updates, and promotions. Follow us on our social networks.

Certification issued by ISSCA and endorsed by the Universidad Autónoma del BENI: UAB and by the Atlantic International University

TOP